Actinium Pharmaceuticals, Inc.
501 Fifth Avenue
New York City
221 articles with Actinium Pharmaceuticals, Inc.
Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers
Studies observed minimal cumulative radiation exposure to clinical staff providing care to patients treated with Iomab-B in the SIERRA trial of 0.09 mSv, contributing minimal exposure to the 50 mSv annual occupational dose limit
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Actinium poster selected from more than 1,110 posters presented at SNMMI awarded second place in oncology therapeutics track
Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Actinium Pharmaceuticals, Inc. announced at SNMMI or the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting that effective lymphodepletion with the radioisotope Lu-177 or lutetium-177 was achieved with its ACT or Adoptive Cell Therapy program for achieving safe, effective and transient lymphodepletion prior to the administration of CAR-T and other adoptive cell therapies.
Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Actinium Pharmaceuticals, Inc. announced its presence at the upcoming SNMMI or Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting being held June 22nd – 25th in Anaheim, California.
Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO
Lower circulating leukemia tumor burden achieved prior to bone marrow transplant with single agent Iomab-B with 98% peripheral blast reduction by day 3 and 100% peripheral blast reduction by day 8
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
Actinium Pharmaceuticals, Inc. announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 ASCO or American Society of Clinical Oncology Annual Meeting that is being held from May 31st – June 4th at McCormick Place, in Chicago.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Niva Almaula, Ph.D. as Chief Business Officer, effective immediately
Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
The Company also announced the pricing of warrants to purchase up to 42,860,000 shares of common stock at an exercise price of $0.50 per share and with a term of 5 years commencing on the date of issuance.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase additional shares of its common stock in an underwritten public offering.
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) that was held on April 1 – 4, 2019 in Ottawa, Canada
Studies observed increase in double-stranded DNA breaks and reduction in MCL-1 levels in cell lines resistant to venetoclax following Actimab exposure
Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
Actinium's AWE Technology Platform is Being Applied to Generate Antibody Radiation-Conjugates with Select Astellas Targeting Agents
Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
Two oral presentations, four poster presentations and panel participation will highlight Actinium's AWE technology platform, clinical programs, next-generation ARC's and the commercial renaissance of radiopharmaceuticals
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
Poster supports rationale for recently initiated Phase 1/2 doublet clinical trial studying novel combination of Actimab-A and venetoclax and planned Phase 1/2 triplet combination trial of Actimab-A and venetoclax with a hypomethylating agent
Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
Actinium Pharmaceuticals, Inc. reported its financial results for the fourth quarter and year ended December 31, 2018 as well as provided corporate and operational updates on clinical trials, research and development, recent hires, and intellectual property.
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs.
Broad intellectual property portfolio, know-how, and trade secrets support Actinium's leadership position in Antibody Radiation-Conjugates, Targeted Conditioning and Actinium-225 based therapies
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, being held March 19-20 at the Westin Grand Central Hotel in New York City.
Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that new data from the ongoing pivotal Phase 3 SIERRA trial for Iomab-B was reported in a late breaking oral presentation at the 2019 Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR (TCT Meetings) that was held on February 20th – 24th
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
In vivo studies demonstrate CD45 targeting ARC effectively lymphodepletes, allowing cells to expand while sparing bone marrow stem cells, red blood cells and platelets